{"Title": ["Here's Why Athersys Stock Is Soaring Today", "Thursday's ETF Movers: XBI, EMLP", "Thursday Sector Leaders: Grocery & Drug Stores, Biotechnology Stocks", "Thursday 6/25 Insider Buying Report: WSBC, ATHX", "MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings", "Here's Why Athersys Rose 26.5% in May", "Athersys (ATHX) Q1 2020 Earnings Call Transcript", "EXCLUSIVE-U.S. companies got emergency government loans despite having months of cash", "Here's Why Athersys Stock Is Soaring Today", "Health Care Sector Update for 05/01/2020: IMGN,SGEN,MOH,MGLN,ATHX", "Health Care Sector Update for 05/01/2020: SGEN,MOH,MGLN,ATHX", "Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?", "BUZZ-U.S. STOCKS ON THE MOVE-Roku, Rite Aid, Jack in the Box, ThermoGenesis", "Athersys Stock Tumbles as Much as 27.7% on a Public Offering", "BUZZ-U.S. STOCKS ON THE MOVE-Edison Nation, Soligenix, Arcus Biosciences, Bed Bath & Beyond", "BUZZ-U.S. STOCKS ON THE MOVE-Bed Bath & Beyond, TSMC, Calithera Biosciences, Soligenix", "Here's Why Athersys Tumbled 23.3% in April", "Health Care Sector Update for 04/15/2020: ATHX,APDN,TDOC", "AMRN Chugs Along, ATHX To Initiate Pivotal COVID-19 Trial, WORX Soars 550%", "BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Amazon.com, Dish Network, GE, AMC Entertainment, Aurora Cannabis", "BUZZ-U.S. STOCKS ON THE MOVE-Amazon.com, Netflix, Royal Caribbean Cruises, Sabre Corp, Pluristem Therapeutics", "Athersys Approved To Start MultiStem Therapy Trial For COVID-19-Induced ARD", "BUZZ-U.S. STOCKS ON THE MOVE-Carnival Corp, Gilead Sciencs, Pluristem Therapeutics, Dropbox, Scworx, Quintana Energy", "Health Care Sector Update for 03/30/2020: REGN,ATHX,JNJ,BRKR", "Health Care Sector Update for 04/15/2020: VIVE,APDN,TDOC,ATHX", "Athersys (ATHX) Q3 2019 Earnings Call Transcript", "Athersys (ATHX) Q2 2019 Earnings Call Transcript", "Here's Why Athersys Rose as Much as 15.2% Today", "6 Top Gainers In Healthcare Sector (ATOS, AKTX, ATHX...)", "Here's Why Athersys Is Soaring Today", "Mid-Afternoon Market Update: Dow Rises Over 100 Points; Akari Therapeutics Shares Spike Higher", "What Makes Athersys (ATHX) a New Buy Stock", "Health Care Sector Update for 03/30/2020: ATHX,JNJ,BRKR", "Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?", "Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study", "Mid-Day Market Update: Accuray Jumps Following Strong Q2 Results; Rexahn Pharmaceuticals Shares Slide", "Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?", "Health Care Sector Update for 01/23/2019: BLPH, ATHX, JNJ, PFE, MRK, ABT, AMGN", "Health Care Sector Update for 01/23/2019: BLUE,CNMD,ATHX,BLPH", "Health Care Sector Update for 01/23/2019: CNMD,ATHX,BLPH", "Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript", "Alnylam Files Clinical Trial Application for ALN-AAT02 in UK", "Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo", "Medicines Company to Continue Inclisiran Studies as Planned", "The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion", "IPOs and Foreign Investment Propel Biotech: 4 Top Picks", "Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year?", "4 Biotech Stocks to Bet on in the Second Half of 2018", "Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%", "Top Ranked Momentum Stocks to Buy for June 12th", "Monday Sector Laggards: Biotechnology, General Contractors & Builders", "Wall Street Sees Mixed Open; Jobless Claims Edge Lower Amid Tight Labor Market", "US Futures Mixed; Jobless Data on Tap", "The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals", "\"Right To Try\" Brings Good News for Biotech Sector: 5 Picks", "5 Biotech Stocks to Boost Your Portfolio\u2019s Health This Year", "Athersys Enters Oversold Territory", "BioMarin's Palynziq Gets FDA Approval for Phenylketonuria", "INSYS Gets Negative FDA Recommendation for Pain Candidate", "Moving Average Crossover Alert: Athersys, Inc. (ATHX)", "Athersys (ATHX) in Focus: Stock Moves 7.2% Higher", "Wall Street Tips Lower Ahead of Fed Minutes", "U.S. Futures Cautiously Lower Ahead of Fed Minutes", "Mid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher", "5 Biotech Stocks to Boost Your Portfolio's Health This Year", "Athersys (ATHX) in Focus: Stock Moves 10.22% Higher", "Wednesday Sector Leaders: Drugs, Biotechnology Stocks", "Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge", "Can the Rally in Athersys (ATHX) Shares Continue?", "Here's What Might Be Pushing Up Shares of Athersys, Inc. Today", "Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?", "Midday Update: Averages Mixed as Wall Street Waits For Direction From Fed Speakers, Q4 GDP", "Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan", "Close Update: Stock Mixed as Wall Street Pauses Before More Fed-Speak, GDP Revision", "12.3% of VTWV Holdings Seeing Recent Insider Buys", "Forget Gilead, Buy These Small-Cap Biotech Stocks Instead", "Earnings Reaction History: Athersys, Inc., 28.6% Follow-Through Indicator, 5.7% Sensitive", "Wednesday 2/1 Insider Buying Report: ANAB, ATHX", "Mid-Day Market Update: Crude Oil Down 2%; Stonegate Mortgage Shares Spike Higher", "Mid-Morning Market Update: Markets Mostly Flat; Alphabet Profit Misses Views", "Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage", "Mid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide", "Ironwood, Allergan Report Positive Linzess IBS-C Study Data", "Alexion Soliris Fails in Phase II/III Delayed Graft Function Study", "Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy", "Celgene (CELG) Otezla Approved in Japan for Two Indications", "Emergent BioSolutions (EBS) in Focus: Stock Rises 18.9%", "Pfizer Leukemia Drug Meets Primary Endpoint in Phase III", "Health Care Sector Update for 01/27/2017: ATHX,MATN,NOVN", "Aimmune Closes Enrolment in Phase III Peanut Allergy Study", "Foamix Completes Enrolment in Phase III Acne Drug Studies", "Epizyme Tazemetostat Gets Fast Track Designation in U.S.", "Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health", "HCA Holdings Announces Share Repurchase Plan Worth $2B", "New Strong Buy Stocks for November 14th", "Athersys (ATHX) Shows Strength: Stock Moves 5.1% Higher", "Roche Presents Positive Follicular Lymphoma Data on Gazvya", "Earnings Reaction History: Athersys, Inc., 37.5% Follow-Through Indicator, 5.4% Sensitive", "Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide", "Mid-Afternoon Market Update: FormFactor Drops On Weak Forecast; ConforMIS Shares Gain", "Mid-Afternoon Market Update: US Stocks Gain; Sunedison Shares Tumble", "Athersys (ATHX) Shows Strength: Stock Soars 19.1%", "Midday Update: Stocks Rally on Energy Market Gains, New Spin on Draghi's Hawkish Comment", "Athersys (ATHX) Worth a Look: Stock Adds 7.1% in Session", "Health Care Sector Update for 09/28/2016: ATHX, AVXL, BIIB, GALT", "Earnings Reaction History: Athersys, Inc., 37.5% Follow-Through Indicator, 5.4% Sensitive", "Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide", "Mid-Afternoon Market Update: Dow Slides 100 Points; Container Store Shares Down On Weak Results", "Health Care Sector Update for 01/08/2016: ATHX,NEPT,GI", "Health Care Sector Update for 11/19/2015: LLY, MRK, ATHX, AMAG", "Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog", "Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog", "Health Care Sector Update for 02/18/2016: AERI, ATHX, CSLT", "The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases", "Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog", "Athersys (ATHX) Worth Watching: Stock Gains 9.5% - Tale of the Tape", "Why Athersys, Inc. Shares Are Soaring Higher Today", "Athersys (ATHX): An Off-the-Radar Potential Winner - Tale of the Tape", "Athersys (ATHX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape", "Why Athersys (ATHX) Could Be Positioned for a Surge? - Tale of the Tape", "Athersys (ATHX) Enters Oversold Territory - Tale of the Tape", "Health Care Sector Update for 03/02/2015: ATHX,OHRP,PCRX", "Athersys, Inc. (ATHX) in Focus: Stock Jumps 5.1% - Tale of the Tape", "Monday Sector Leaders: Drugs, Biotechnology Stocks", "Athersys (ATHX) Looks Good: Stock Adds 13.7% in Session - Tale of the Tape", "Athersys (ATHX) Shares March Higher, Can It Continue? - Tale of the Tape", "Athersys Finishes Enrollment for MultiStem Cell Therapy Trial - Analyst Blog", "Athersys Loss In Line with Expectations, Revenues Down Y/Y - Analyst Blog", "Earnings Reaction History: Athersys, Inc., 60.0% Follow-Through Indicator, 4.3% Sensitive", "Zacks Rank #5 Additions for Thursday - Tale of the Tape", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Monday Sector Laggards: Biotechnology, Education & Training Services", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Zacks Rank #5 Additions for Wednesday - Tale of the Tape", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Zacks Rank #5 Additions for Friday - Tale of the Tape", "Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog", "Zacks Rank #5 Additions for Thursday - Tale of the Tape", "MultiStem Overshadows Q4 Loss at Athersys - Analyst Blog", "Athersys Attains 52-Week High - Analyst Blog", "GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2% - Tale of the Tape", "Athersys (ATHX) in Focus: Stock Moves 6.3% Higher - Tale of the Tape", "Will Athersys, Inc. (ATHX) Continue to Surge Higher? - Tale of the Tape", "Amicus Therapeutics Raises Funds - Analyst Blog", "Zacks Rank #5 Additions for Wednesday - Tale of the Tape", "Pipeline Progress at Athersys - Analyst Blog", "Athersys (ATHX) in Focus: Stock Moves 6.8% Higher - Tale of the Tape", "Athersys to Raise Funds - Analyst Blog", "Athersys (ATHX) Catches Eye: Stock Jumps 5.5% - Tale of the Tape", "Athersys (ATHX) Jumps: Stock Rises by 9.2% - Tale of the Tape", "Athersys Narrows Loss, Shares Rise - Analyst Blog", "Celgene's Pipeline Encourages - Analyst Blog", "Athersys, Inc. (ATHX) Jumps: Stock Up 6.9% - Tale of the Tape", "Pipeline Progress at Athersys - Analyst Blog", "BioLineRx Files for BL-7010 Study Initiation - Analyst Blog", "Biogen Upped to Outperform - Analyst Blog", "Narrower-than-Expected Loss at Athersys - Analyst Blog", "Can the Recent Uptrend Continue for Athersys, Inc. (ATHX)? - Tale of the Tape", "Trade the Earnings: Athersys, Inc.", "Manufacturing Issues Hit Hospira - Analyst Blog", "Spectrum Pharma Reports 1Q Loss - Analyst Blog", "Elan in Royalty Deal with THRX - Analyst Blog", "After-Hours Earnings Report for May 14, 2013 : A, EXP, VIPS, PLAB, VOXX, ATHX, FENG, ALXA, TKMR, PRMW, QBAK, TXCC", "Celgene Attains 52-Week High - Analyst Blog", "PDL BioPharma Misses Earnings Ests - Analyst Blog", "Medivation Loss Narrower Than Expected - Analyst Blog", "Glaxo/THRX's Breo Ellipta Gets FDA Nod - Analyst Blog", "Wider-Than-Expected Loss at Athersys - Analyst Blog", "Dendreon Narrows 1Q Loss - Analyst Blog", "Positive Data on Celgene's Apremilast - Analyst Blog", "Earnings Miss at Perrigo - Analyst Blog", "Alnylam Narrows Loss, Sales Fall - Analyst Blog", "Isis Initiates ISIS-STAT3 Study - Analyst Blog", "Gilead Misses on Earnings, Sales in 1Q - Analyst Blog", "Negative Opinion on AVEO/ALPMY Candidate - Analyst Blog", "Disappointing 1Q Earnings for IART - Analyst Blog", "Affymetrix Reports Disappointing 1Q - Analyst Blog", "Glaxo's Trametinib Delayed - Analyst Blog", "CHMP Backs VIVUS' Spedra - Analyst Blog", "Double Setback for Gilead - Analyst Blog", "Geron Narrows Loss; Cuts Jobs - Analyst Blog", "CHMP in Favor of Celgene's Revlimid - Analyst Blog", "Earnings Increase at The Medicines Co. - Analyst Blog", "Loss at Aegerion Narrower Than Expected - Analyst Blog", "AstraZeneca Earnings Tumble Y/Y - Analyst Blog", "Biogen's Earnings Surpass Expectations - Analyst Blog", "Earnings Beat at Alexion, Ups View - Analyst Blog", "InterMune Cuts Loss, Affirms View - Analyst Blog", "Tax Benefit Boosts Amgen Earnings - Analyst Blog", "Loss Widens at Ironwood - Analyst Blog", "AZN/BIND Therapeutics Ink Deal - Analyst Blog", "Bayer Earnings Rise Y/Y - Analyst Blog", "Sanofi's Vaccine Gets EU Approval - Analyst Blog", "Vertex CF Candidate Impresses - Analyst Blog", "AZN Inks Biomarker Discovery Deal - Analyst Blog", "Omeros' OMS721 Files for Orphan Drug Status - Analyst Blog", "BMY to Expand Facility, Hire 350 - Analyst Blog", "Synergy Pharma Prices Public Offering - Analyst Blog", "Aeterna Zentaris/Ergomed Join Forces - Analyst Blog", "PDL BioPharma to Finance Avinger - Analyst Blog", "Alkermes Announces Restructuring Plan - Analyst Blog", "Affymetrix to Disappoint in 1Q - Analyst Blog", "Synergy Pharma to Raise Funds - Analyst Blog", "Regeneron Rated Neutral Again - Analyst Blog", "Positive Data on PCYC's Ibrutinib - Analyst Blog", "Sanofi Unveils Bond Issue Pricing - Analyst Blog", "AZN Reports Data on Fostamatinib - Analyst Blog", "BioMarin Attains 52-Week High - Analyst Blog", "QLT Sells PPDS Technology - Analyst Blog", "Orphan Status for Insmed's Arikace - Analyst Blog", "BioMarin Files CTA for BMN-190 - Analyst Blog", "Perrigo Touches 52-Week High - Analyst Blog", "Celgene Reaches 52-Week High - Analyst Blog", "Perrigo Buys Velcera - Analyst Blog", "BMRN Seeks US Approval of Vimizim - Analyst Blog", "ISIS Initiates ISIS-APOA Study - Analyst Blog", "Bad News for Alexion, Shares Down - Analyst Blog", "FDA Approves Biogen's Tecfidera - Analyst Blog", "Balanced View on Gilead Sciences - Analyst Blog", "Good News for Simcere Pharma - Analyst Blog", "Positive Data on Biogen's Plegridy - Analyst Blog", "CHMP Negative on Gentium Candidate - Analyst Blog", "CHMP Positive on Biogen's Tecfidera - Analyst Blog", "Gilead's HCV Study to Continue - Analyst Blog", "Positive Data on Amgen Candidate - Analyst Blog", "Synergy Posts Wider Loss - Analyst Blog", "Alnylam Initiates ALN-TTRsc Study - Analyst Blog", "Zacks Rank #1 Addition for Friday - Tale of the Tape", "Alexion Pharma Upgraded to Outperform - Analyst Blog", "9 Biotech Penny Stocks to Buy", "9 Biotech Penny Stocks to Buy", "More Protection for Biogen's Tecfidera - Analyst Blog"], "Elapsed Time": ["1 DAY AGO", "1 DAY AGO", "1 DAY AGO", "1 DAY AGO", "3 DAYS AGO", "JUN 9, 2020", "MAY 9, 2020", "MAY 7, 2020", "1 DAY AGO", "MAY 1, 2020", "MAY 1, 2020", "APR 28, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "MAY 4, 2020", "APR 15, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "MAR 30, 2020", "APR 15, 2020", "NOV 7, 2019", "AUG 8, 2019", "MAY 14, 2019", "APR 23, 2019", "APR 23, 2019", "APR 23, 2019", "MAR 19, 2019", "MAR 30, 2020", "MAR 7, 2019", "JAN 24, 2019", "JAN 23, 2019", "JAN 23, 2019", "JAN 23, 2019", "JAN 23, 2019", "JAN 23, 2019", "MAR 14, 2019", "OCT 4, 2018", "OCT 3, 2018", "OCT 3, 2018", "SEP 14, 2018", "SEP 13, 2018", "AUG 16, 2018", "JUN 29, 2018", "OCT 8, 2018", "JUN 12, 2018", "JUN 11, 2018", "JUN 7, 2018", "JUN 7, 2018", "JUN 4, 2018", "JUN 1, 2018", "MAY 31, 2018", "JUN 22, 2018", "MAY 25, 2018", "MAY 23, 2018", "MAY 22, 2018", "OCT 12, 2017", "OCT 11, 2017", "OCT 11, 2017", "OCT 10, 2017", "MAY 31, 2018", "SEP 7, 2017", "JUN 21, 2017", "JUN 8, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 30, 2017", "MAR 29, 2017", "OCT 10, 2017", "MAR 29, 2017", "MAR 22, 2017", "MAR 15, 2017", "MAR 9, 2017", "FEB 1, 2017", "JAN 27, 2017", "JAN 27, 2017", "MAR 29, 2017", "JAN 27, 2017", "DEC 23, 2016", "DEC 22, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 12, 2016", "DEC 6, 2016", "JAN 27, 2017", "NOV 30, 2016", "NOV 30, 2016", "NOV 29, 2016", "NOV 25, 2016", "NOV 15, 2016", "NOV 14, 2016", "SEP 29, 2016", "DEC 6, 2016", "AUG 9, 2016", "MAR 30, 2016", "MAR 30, 2016", "MAR 22, 2016", "MAR 14, 2016", "MAR 11, 2016", "FEB 26, 2016", "SEP 28, 2016", "AUG 9, 2016", "JAN 8, 2016", "JAN 8, 2016", "JAN 8, 2016", "NOV 19, 2015", "MAY 13, 2015", "MAY 13, 2015", "FEB 18, 2016", "APR 23, 2015", "APR 20, 2015", "APR 9, 2015", "APR 8, 2015", "APR 1, 2015", "MAR 30, 2015", "MAR 26, 2015", "MAY 7, 2015", "MAR 2, 2015", "FEB 24, 2015", "FEB 23, 2015", "JAN 2, 2015", "JAN 2, 2015", "DEC 30, 2014", "AUG 13, 2014", "MAR 12, 2015", "MAY 1, 2014", "APR 28, 2014", "APR 28, 2014", "APR 21, 2014", "APR 16, 2014", "APR 14, 2014", "APR 4, 2014", "MAY 14, 2014", "MAR 20, 2014", "MAR 14, 2014", "JAN 7, 2014", "JAN 7, 2014", "JAN 7, 2014", "JAN 3, 2014", "JAN 2, 2014", "MAR 26, 2014", "DEC 24, 2013", "DEC 16, 2013", "DEC 2, 2013", "NOV 26, 2013", "NOV 22, 2013", "NOV 21, 2013", "OCT 7, 2013", "DEC 24, 2013", "DEC 24, 2013", "SEP 25, 2013", "SEP 19, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 13, 2013", "OCT 7, 2013", "MAY 14, 2013", "MAY 14, 2013", "MAY 14, 2013", "MAY 14, 2013", "MAY 13, 2013", "MAY 13, 2013", "MAY 13, 2013", "MAY 15, 2013", "MAY 10, 2013", "MAY 9, 2013", "MAY 7, 2013", "MAY 7, 2013", "MAY 7, 2013", "MAY 3, 2013", "MAY 3, 2013", "MAY 10, 2013", "MAY 2, 2013", "MAY 2, 2013", "APR 30, 2013", "APR 30, 2013", "APR 29, 2013", "APR 29, 2013", "APR 26, 2013", "MAY 3, 2013", "APR 26, 2013", "APR 25, 2013", "APR 25, 2013", "APR 25, 2013", "APR 24, 2013", "APR 24, 2013", "APR 23, 2013", "APR 26, 2013", "APR 22, 2013", "APR 19, 2013", "APR 18, 2013", "APR 18, 2013", "APR 12, 2013", "APR 12, 2013", "APR 11, 2013", "APR 23, 2013", "APR 11, 2013", "APR 10, 2013", "APR 10, 2013", "APR 10, 2013", "APR 10, 2013", "APR 9, 2013", "APR 8, 2013", "APR 11, 2013", "APR 5, 2013", "APR 4, 2013", "APR 3, 2013", "APR 3, 2013", "APR 2, 2013", "APR 2, 2013", "APR 2, 2013", "APR 8, 2013", "APR 1, 2013", "MAR 28, 2013", "MAR 28, 2013", "MAR 28, 2013", "MAR 27, 2013", "MAR 26, 2013", "MAR 25, 2013", "APR 1, 2013", "MAR 21, 2013", "MAR 20, 2013", "MAR 19, 2013", "MAR 15, 2013", "MAR 15, 2013", "AUG 30, 2010", "AUG 30, 2010", "MAR 22, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/heres-why-athersys-stock-is-soaring-today-2020-06-25", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-xbi-emlp-2020-06-25", "https://www.nasdaq.com/articles/thursday-sector-leaders%3A-grocery-drug-stores-biotechnology-stocks-2020-06-25", "https://www.nasdaq.com/articles/thursday-6-25-insider-buying-report%3A-wsbc-athx-2020-06-25", "https://www.nasdaq.com/articles/myov-to-report-spirit-1-data-evlo-joins-covid-19-drug-race-nvta-loosens-purse-strings-2020", "https://www.nasdaq.com/articles/heres-why-athersys-rose-26.5-in-may-2020-06-09", "https://www.nasdaq.com/articles/athersys-athx-q1-2020-earnings-call-transcript-2020-05-10", "https://www.nasdaq.com/articles/exclusive-u.s.-companies-got-emergency-government-loans-despite-having-months-of-cash-2020", "https://www.nasdaq.com/articles/heres-why-athersys-stock-is-soaring-today-2020-06-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-01-2020%3A-imgnsgenmohmglnathx-2020-05-01", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-01-2020%3A-sgenmohmglnathx-2020-05-01", "https://www.nasdaq.com/articles/are-stem-cells-the-covid-19-treatment-weve-all-been-waiting-for-2020-04-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-roku-rite-aid-jack-in-the-box-thermogenesis-2020-04-16", "https://www.nasdaq.com/articles/athersys-stock-tumbles-as-much-as-27.7-on-a-public-offering-2020-04-16", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-edison-nation-soligenix-arcus-biosciences-bed-bath-beyond", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-bed-bath-beyond-tsmc-calithera-biosciences-soligenix-2020-04", "https://www.nasdaq.com/articles/heres-why-athersys-tumbled-23.3-in-april-2020-05-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-15-2020%3A-athxapdntdoc-2020-04-15", "https://www.nasdaq.com/articles/amrn-chugs-along-athx-to-initiate-pivotal-covid-19-trial-worx-soars-550-2020-04-13", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-netflix-amazon.com-dish-network-ge-amc-entertainment-aurora", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-amazon.com-netflix-royal-caribbean-cruises-sabre-corp", "https://www.nasdaq.com/articles/athersys-approved-to-start-multistem-therapy-trial-for-covid-19-induced-ard-2020-04-13", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-carnival-corp-gilead-sciencs-pluristem-therapeutics-dropbox", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-30-2020%3A-regnathxjnjbrkr-2020-03-30", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-15-2020%3A-viveapdntdocathx-2020-04-15", "https://www.nasdaq.com/articles/athersys-athx-q3-2019-earnings-call-transcript-2019-11-07", "https://www.nasdaq.com/articles/athersys-athx-q2-2019-earnings-call-transcript-2019-08-08", "https://www.nasdaq.com/articles/heres-why-athersys-rose-much-15.2-today-2019-05-14", "https://www.nasdaq.com/articles/6-top-gainers-healthcare-sector-atos-aktx-athx...-2019-04-23", "https://www.nasdaq.com/articles/heres-why-athersys-soaring-today-2019-04-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update%3A-dow-rises-over-100-points-akari-therapeutics-shares-spike", "https://www.nasdaq.com/articles/what-makes-athersys-athx-a-new-buy-stock-2019-03-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-30-2020%3A-athxjnjbrkr-2020-03-30", "https://www.nasdaq.com/articles/athersys-athx-q4-earnings%3A-whats-in-store-for-the-stock-2019-03-07", "https://www.nasdaq.com/articles/athersys-athx-multistem-cell-therapy-succeeds-in-study-2019-01-24", "https://www.nasdaq.com/articles/mid-day-market-update-accuray-jumps-following-strong-q2-results-rexahn-pharmaceuticals", "https://www.nasdaq.com/articles/athersys-athx-upgraded-to-buy%3A-what-does-it-mean-for-the-stock-2019-01-23", "https://www.nasdaq.com/articles/health-care-sector-update-01232019-blph-athx-jnj-pfe-mrk-abt-amgn-2019-01-23", "https://www.nasdaq.com/articles/health-care-sector-update-01232019-bluecnmdathxblph-2019-01-23", "https://www.nasdaq.com/articles/health-care-sector-update-01232019-cnmdathxblph-2019-01-23", "https://www.nasdaq.com/articles/athersys-inc-athx-q4-2018-earnings-conference-call-transcript-2019-03-14", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat02-in-uk-2018-10-04", "https://www.nasdaq.com/articles/amgen-gets-fda-nod-for-once-weekly-regimen-of-kyprolis-combo-2018-10-03", "https://www.nasdaq.com/articles/medicines-company-to-continue-inclisiran-studies-as-planned-2018-10-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-illumina-celgene-athersys-and-achillion-2018-09-14", "https://www.nasdaq.com/articles/ipos-and-foreign-investment-propel-biotech-4-top-picks-2018-09-13", "https://www.nasdaq.com/articles/is-athersys-athx-stock-outpacing-its-medical-peers-this-year-2018-08-16", "https://www.nasdaq.com/articles/4-biotech-stocks-bet-second-half-2018-2018-06-29", "https://www.nasdaq.com/articles/audentes-therapeutics-bold-catches-eye%3A-stock-jumps-7-2018-10-08", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-june-12th-2018-06-12", "https://www.nasdaq.com/articles/monday-sector-laggards-biotechnology-general-contractors-builders-2018-06-11", "https://www.nasdaq.com/articles/wall-street-sees-mixed-open-jobless-claims-edge-lower-amid-tight-labor-market-2018-06-07", "https://www.nasdaq.com/articles/us-futures-mixed-jobless-data-tap-2018-06-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-illumina-athersys-eyepoint-pharmaceuticals-rhythm", "https://www.nasdaq.com/articles/right-try-brings-good-news-biotech-sector-5-picks-2018-06-01", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31-0", "https://www.nasdaq.com/articles/athersys-enters-oversold-territory-2018-06-22", "https://www.nasdaq.com/articles/biomarins-palynziq-gets-fda-approval-for-phenylketonuria-2018-05-25", "https://www.nasdaq.com/articles/insys-gets-negative-fda-recommendation-for-pain-candidate-2018-05-23", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-athersys-inc.-athx-2018-05-22", "https://www.nasdaq.com/articles/athersys-athx-in-focus%3A-stock-moves-7.2-higher-2017-10-12", "https://www.nasdaq.com/articles/wall-street-tips-lower-ahead-fed-minutes-2017-10-11", "https://www.nasdaq.com/articles/us-futures-cautiously-lower-ahead-fed-minutes-2017-10-11", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-27-mannkind-shares-spike-higher-2017-10-10", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31", "https://www.nasdaq.com/articles/athersys-athx-in-focus%3A-stock-moves-10.22-higher-2017-09-07", "https://www.nasdaq.com/articles/wednesday-sector-leaders-drugs-biotechnology-stocks-2017-06-21", "https://www.nasdaq.com/articles/why-athersys-inc.-athx-could-be-positioned-for-a-surge-2017-06-08", "https://www.nasdaq.com/articles/can-the-rally-in-athersys-athx-shares-continue-2017-03-31", "https://www.nasdaq.com/articles/heres-what-might-be-pushing-shares-athersys-inc-today-2017-03-31", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-athersys-athx-stock-2017-03-30", "https://www.nasdaq.com/articles/midday-update-averages-mixed-wall-street-waits-direction-fed-speakers-q4-gdp-2017-03-29", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-wal-mart-reports-20b-buyback-plan-2017-10-10", "https://www.nasdaq.com/articles/close-update-stock-mixed-wall-street-pauses-more-fed-speak-gdp-revision-2017-03-29", "https://www.nasdaq.com/articles/123-vtwv-holdings-seeing-recent-insider-buys-2017-03-22", "https://www.nasdaq.com/articles/forget-gilead-buy-these-small-cap-biotech-stocks-instead-2017-03-15", "https://www.nasdaq.com/articles/earnings-reaction-history-athersys-inc-286-follow-through-indicator-57-sensitive-2017-03", "https://www.nasdaq.com/articles/wednesday-21-insider-buying-report-anab-athx-2017-02-01", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-down-2-stonegate-mortgage-shares-spike-higher-2017-01-27", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-flat-alphabet-profit-misses-views-2017-01-27", "https://www.nasdaq.com/articles/athersys-athx-stock-rallies-as-william-blair-initiates-coverage-2017-03-29", "https://www.nasdaq.com/articles/mid-afternoon-market-update-celestica-rises-earnings-beat-keyw-shares-slide-2017-01-27", "https://www.nasdaq.com/articles/ironwood-allergan-report-positive-linzess-ibs-c-study-data-2016-12-23", "https://www.nasdaq.com/articles/alexion-soliris-fails-in-phase-ii-iii-delayed-graft-function-study-2016-12-22", "https://www.nasdaq.com/articles/bristol-myers-psioxus-ink-deal-for-oncolytic-virus-therapy-2016-12-21", "https://www.nasdaq.com/articles/celgene-celg-otezla-approved-in-japan-for-two-indications-2016-12-21", "https://www.nasdaq.com/articles/emergent-biosolutions-ebs-in-focus%3A-stock-rises-18.9-2016-12-12", "https://www.nasdaq.com/articles/pfizer-leukemia-drug-meets-primary-endpoint-in-phase-iii-2016-12-06", "https://www.nasdaq.com/articles/health-care-sector-update-01272017-athxmatnnovn-2017-01-27", "https://www.nasdaq.com/articles/aimmune-closes-enrolment-in-phase-iii-peanut-allergy-study-2016-11-30", "https://www.nasdaq.com/articles/foamix-completes-enrolment-in-phase-iii-acne-drug-studies-2016-11-30", "https://www.nasdaq.com/articles/epizyme-tazemetostat-gets-fast-track-designation-in-u.s.-2016-11-29", "https://www.nasdaq.com/articles/navidea-inks-deal-to-to-sell-lymphoseek-to-cardinal-health-2016-11-25", "https://www.nasdaq.com/articles/hca-holdings-announces-share-repurchase-plan-worth-%242b-2016-11-15", "https://www.nasdaq.com/articles/new-strong-buy-stocks-november-14th-2016-11-14", "https://www.nasdaq.com/articles/athersys-athx-shows-strength%3A-stock-moves-5.1-higher-2016-09-29", "https://www.nasdaq.com/articles/roche-presents-positive-follicular-lymphoma-data-on-gazvya-2016-12-06", "https://www.nasdaq.com/articles/earnings-reaction-history-athersys-inc-375-follow-through-indicator-54-sensitive-2016-08", "https://www.nasdaq.com/articles/mid-day-market-update-acadia-pharmaceuticals-rises-following-fda-panel-vote-verint-systems", "https://www.nasdaq.com/articles/mid-afternoon-market-update-formfactor-drops-weak-forecast-conformis-shares-gain-2016-03", "https://www.nasdaq.com/articles/mid-afternoon-market-update-us-stocks-gain-sunedison-shares-tumble-2016-03-22", "https://www.nasdaq.com/articles/athersys-athx-shows-strength%3A-stock-soars-19.1-2016-03-14", "https://www.nasdaq.com/articles/midday-update-stocks-rally-energy-market-gains-new-spin-draghis-hawkish-comment-2016-03-11", "https://www.nasdaq.com/articles/athersys-athx-worth-a-look%3A-stock-adds-7.1-in-session-2016-02-26", "https://www.nasdaq.com/articles/health-care-sector-update-09282016-athx-avxl-biib-galt-2016-09-28", "https://www.nasdaq.com/articles/earnings-reaction-history-athersys-inc-375-follow-through-indicator-54-sensitive-2016-08", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-turn-lower-ngl-energy-partners-shares-spike-higher-2016-01", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-slides-100-points-container-store-shares-down-weak-results", "https://www.nasdaq.com/articles/health-care-sector-update-01082016-athxneptgi-2016-01-08", "https://www.nasdaq.com/articles/health-care-sector-update-11192015-lly-mrk-athx-amag-2015-11-19", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-orkambi-wins-fda-panel-backing-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/orexigen-slumps-as-new-contrave-data-comes-to-light-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/health-care-sector-update-02182016-aeri-athx-cslt-2016-02-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-medicines-athersys-and-alnylam-press-releases", "https://www.nasdaq.com/articles/athersys-slumps-as-multistem-fails-in-mid-stage-study-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/athersys-athx-worth-watching%3A-stock-gains-9.5-tale-of-the-tape-2015-04-09", "https://www.nasdaq.com/articles/why-athersys-inc-shares-are-soaring-higher-today-2015-04-08", "https://www.nasdaq.com/articles/athersys-athx%3A-an-off-the-radar-potential-winner-tale-of-the-tape-2015-04-01", "https://www.nasdaq.com/articles/athersys-athx%3A-strong-industry-solid-earnings-estimate-revisions-tale-of-the-tape-2015-03", "https://www.nasdaq.com/articles/why-athersys-athx-could-be-positioned-for-a-surge-tale-of-the-tape-2015-03-26", "https://www.nasdaq.com/articles/athersys-athx-enters-oversold-territory-tale-of-the-tape-2015-05-07", "https://www.nasdaq.com/articles/health-care-sector-update-03022015-athxohrppcrx-2015-03-02", "https://www.nasdaq.com/articles/athersys-inc.-athx-in-focus%3A-stock-jumps-5.1-tale-of-the-tape-2015-02-24-0", "https://www.nasdaq.com/articles/monday-sector-leaders-drugs-biotechnology-stocks-2015-02-23", "https://www.nasdaq.com/articles/athersys-athx-looks-good%3A-stock-adds-13.7-in-session-tale-of-the-tape-2015-01-02", "https://www.nasdaq.com/articles/athersys-athx-shares-march-higher-can-it-continue-tale-of-the-tape-2015-01-02", "https://www.nasdaq.com/articles/athersys-finishes-enrollment-for-multistem-cell-therapy-trial-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/athersys-loss-in-line-with-expectations-revenues-down-y-y-analyst-blog-2014-08-13", "https://www.nasdaq.com/articles/earnings-reaction-history-athersys-inc-600-follow-through-indicator-43-sensitive-2015-03", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-thursday-tale-of-the-tape-2014-05-01", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-04-28", "https://www.nasdaq.com/articles/monday-sector-laggards-biotechnology-education-training-services-2014-04-28", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-04-21", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-wednesday-tale-of-the-tape-2014-04-16", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-04-14", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-friday-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/athersys-reports-wider-than-expected-q1-loss-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-thursday-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/multistem-overshadows-q4-loss-at-athersys-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/athersys-attains-52-week-high-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/gtx-inc.-gtxi-worth-watching%3A-stock-rises-7.2-tale-of-the-tape-2014-01-07", "https://www.nasdaq.com/articles/athersys-athx-in-focus%3A-stock-moves-6.3-higher-tale-of-the-tape-2014-01-07", "https://www.nasdaq.com/articles/will-athersys-inc.-athx-continue-to-surge-higher-tale-of-the-tape-2014-01-03", "https://www.nasdaq.com/articles/amicus-therapeutics-raises-funds-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-wednesday-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/pipeline-progress-at-athersys-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/athersys-athx-in-focus%3A-stock-moves-6.8-higher-tale-of-the-tape-2013-12-16", "https://www.nasdaq.com/articles/athersys-to-raise-funds-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/athersys-athx-catches-eye%3A-stock-jumps-5.5-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/athersys-athx-jumps%3A-stock-rises-by-9.2-tale-of-the-tape-2013-11-22", "https://www.nasdaq.com/articles/athersys-narrows-loss-shares-rise-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/celgenes-pipeline-encourages-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/athersys-inc.-athx-jumps%3A-stock-up-6.9-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/pipeline-progress-at-athersys-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/biolinerx-files-for-bl-7010-study-initiation-analyst-blog-2013-09-25", "https://www.nasdaq.com/articles/biogen-upped-to-outperform-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-athersys-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/can-the-recent-uptrend-continue-for-athersys-inc.-athx-tale-of-the-tape-2013-08-19", "https://www.nasdaq.com/articles/trade-earnings-athersys-inc-2013-08-13", "https://www.nasdaq.com/articles/manufacturing-issues-hit-hospira-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/spectrum-pharma-reports-1q-loss-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/elan-in-royalty-deal-with-thrx-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-14-2013-exp-vips-plab-voxx-athx-feng-alxa-tkmr-prmw-qbak", "https://www.nasdaq.com/articles/celgene-attains-52-week-high-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/pdl-biopharma-misses-earnings-ests-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/medivation-loss-narrower-than-expected-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/glaxo-thrxs-breo-ellipta-gets-fda-nod-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-athersys-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/dendreon-narrows-1q-loss-analyst-blog-2013-05-10", "https://www.nasdaq.com/articles/positive-data-on-celgenes-apremilast-analyst-blog-2013-05-09", "https://www.nasdaq.com/articles/earnings-miss-at-perrigo-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/alnylam-narrows-loss-sales-fall-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/isis-initiates-isis-stat3-study-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/gilead-misses-on-earnings-sales-in-1q-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/negative-opinion-on-aveo-alpmy-candidate-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/disappointing-1q-earnings-for-iart-analyst-blog-2013-05-10", "https://www.nasdaq.com/articles/affymetrix-reports-disappointing-1q-analyst-blog-2013-05-02", "https://www.nasdaq.com/articles/glaxos-trametinib-delayed-analyst-blog-2013-05-02", "https://www.nasdaq.com/articles/chmp-backs-vivus-spedra-analyst-blog-2013-04-30", "https://www.nasdaq.com/articles/double-setback-for-gilead-analyst-blog-2013-04-30", "https://www.nasdaq.com/articles/geron-narrows-loss-cuts-jobs-analyst-blog-2013-04-29", "https://www.nasdaq.com/articles/chmp-in-favor-of-celgenes-revlimid-analyst-blog-2013-04-29", "https://www.nasdaq.com/articles/earnings-increase-at-the-medicines-co.-analyst-blog-2013-04-26", "https://www.nasdaq.com/articles/loss-at-aegerion-narrower-than-expected-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/astrazeneca-earnings-tumble-y-y-analyst-blog-2013-04-26", "https://www.nasdaq.com/articles/biogens-earnings-surpass-expectations-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/earnings-beat-at-alexion-ups-view-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/intermune-cuts-loss-affirms-view-analyst-blog-2013-04-25", "https://www.nasdaq.com/articles/tax-benefit-boosts-amgen-earnings-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/loss-widens-at-ironwood-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/azn-bind-therapeutics-ink-deal-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/bayer-earnings-rise-y-y-analyst-blog-2013-04-26", "https://www.nasdaq.com/articles/sanofis-vaccine-gets-eu-approval-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/vertex-cf-candidate-impresses-analyst-blog-2013-04-19", "https://www.nasdaq.com/articles/azn-inks-biomarker-discovery-deal-analyst-blog-2013-04-18", "https://www.nasdaq.com/articles/omeros-oms721-files-for-orphan-drug-status-analyst-blog-2013-04-18", "https://www.nasdaq.com/articles/bmy-to-expand-facility-hire-350-analyst-blog-2013-04-12", "https://www.nasdaq.com/articles/synergy-pharma-prices-public-offering-analyst-blog-2013-04-12", "https://www.nasdaq.com/articles/aeterna-zentaris-ergomed-join-forces-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/pdl-biopharma-to-finance-avinger-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/alkermes-announces-restructuring-plan-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/affymetrix-to-disappoint-in-1q-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/synergy-pharma-to-raise-funds-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/regeneron-rated-neutral-again-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/positive-data-on-pcycs-ibrutinib-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/sanofi-unveils-bond-issue-pricing-analyst-blog-2013-04-09", "https://www.nasdaq.com/articles/azn-reports-data-on-fostamatinib-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/biomarin-attains-52-week-high-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/qlt-sells-ppds-technology-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/orphan-status-for-insmeds-arikace-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/biomarin-files-cta-for-bmn-190-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/perrigo-touches-52-week-high-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/celgene-reaches-52-week-high-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/perrigo-buys-velcera-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/bmrn-seeks-us-approval-of-vimizim-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/isis-initiates-isis-apoa-study-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/bad-news-for-alexion-shares-down-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/fda-approves-biogens-tecfidera-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/balanced-view-on-gilead-sciences-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/good-news-for-simcere-pharma-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/positive-data-on-biogens-plegridy-analyst-blog-2013-03-27", "https://www.nasdaq.com/articles/chmp-negative-on-gentium-candidate-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/chmp-positive-on-biogens-tecfidera-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/gileads-hcv-study-to-continue-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/positive-data-on-amgen-candidate-analyst-blog-2013-03-21", "https://www.nasdaq.com/articles/synergy-posts-wider-loss-analyst-blog-2013-03-20", "https://www.nasdaq.com/articles/alnylam-initiates-aln-ttrsc-study-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-friday-tale-of-the-tape-2013-03-15", "https://www.nasdaq.com/articles/alexion-pharma-upgraded-to-outperform-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/9-biotech-penny-stocks-buy-2010-08-30-0", "https://www.nasdaq.com/articles/9-biotech-penny-stocks-buy-2010-08-30", "https://www.nasdaq.com/articles/more-protection-for-biogens-tecfidera-analyst-blog-2013-03-22"], "Content": []}